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A Review of Guidelines And APPRoAcHes to PeRfoRmAnce-BAsed Risk-
sHARinG AGReements AcRoss tHe uk, itAly And tHe netHeRlAnds
Pritchett L, Wiesinger A, Faria-Billinton E, Brown A, Murray G, Stoor L, Nwogu G
Abacus International, Manchester, UK
Objectives: In response to greater health budget restrictions and the rise in costly 
new treatments, manufacturers and payers have increasing interest in performance-
based risk-sharing arrangements (PBRSAs) that address uncertainty and accelerate 
access to medicines. Our objectives were to review guidelines for PBRSA implemen-
tation and the use of PBRSAs in the UK, Italy, and the Netherlands. MethOds: 
A non-systematic review was undertaken using PubMed to identify guidance on 
PBRSA implementation. Appropriate governmental and agency websites in the UK, 
Italy, and the Netherlands were also reviewed to identify PBRSA examples. Key 
considerations for PBRSA implementation and its historical application in the UK, 
Italy and the Netherlands were evaluated. Results: Several key considerations for 
PBRSA implementation were identified from published guidelines. The approach to 
PBRSA implementation varies between countries with regards to: evidence collec-
tion, governance, reporting, and evaluation. While PBRSAs have been applied in the 
UK, simple cost-sharing arrangements are now encouraged due to difficulties with 
the implementation and evaluation of PBRSAs. In Italy, AIFA makes extensive use of 
online monitoring registries to inform their PBRSAs. However, there is no established 
process for implementation. Currently, in the Netherlands all inpatient drugs with a 
budget impact > € 0.6 million and an unacceptable level of uncertainty can be granted 
access via coverage with evidence development arrangements. Both national and 
international registry data are used in the re-evaluation of reimbursement deci-
sions. cOnclusiOns: The approach to PBRSA implementation varied across the 
three countries reviewed, although the objectives for their use were similar across 
the analysed countries. Manufacturers need to consider country-specific factors 
for implementation and key PBRSA considerations identified via our research offer 
guidance for applying PBRSAs in these markets.
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wHicH Risk sHARe AGReements ARe AvAilABle And ARe tHose APPlied in 
GloBAl ReimBuRsement decisions?
Walzer S1, Droeschel D1, Shannon R2
1MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 2Global Health 
Economic Projects, LLC, New York, NY, USA
Objectives: Risk Share Agreements (RSAs) are defined as agreements between 
a payer and a manufacturer where the price level is related to the actual future 
performance of the product. In the last years RSAs were introduced and applied in 
various jurisdictions. MethOds: RSAs in Australia, Canada, Italy, Spain, UK and the 
US were systematically searched for. They were clustered into the type of RSA per 
country and compared to each other. Results: In Australia the main RSA types 
were annual sales caps, indication-wide caps, label caps, price-volume agreements, 
comparator rebates. The details of deeds of agreements/RSAs are generally not 
publicly available. In Canada the final formulary inclusion decisions are made by 
each province separately where confidential contracting with direct discounts are 
preferred. In Italy different contracting mechanisms evolved to payments-by-results 
in the last years with the AIFA patient registry supporting the implementation of 
RSAs. Even though payment-by-results was the main type of RSA, cost sharing, cost 
ceiling, risk sharing and combination types were accepted. In Spain contracting 
has become relevant with the introduction of dual pricing (list price vs reimbursed 
price). Combination RSA types (rebates, price-volume agreements, utilization cap, 
therapeutic positioning, pay-for-performance) were used at all levels whereas most 
regions have discount/rebate volume-based negotiations at hospital levels for high 
budget impact drugs. In the UK many recently launched high cost drugs achieved 
positive NICE guidance only if a patient access scheme was offered; with discount 
“only” schemes as the only one accepted by the NHS. In the US RSA are differently 
used to other markets mainly as coverage with evidence development type and not 
directly linked to the actual price. cOnclusiOns: Currently RSAs are applied in 
different countries, however not in the same way and utilizing the same types for 
RSA with discounts as being the most relevant for payers.
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Lucas F1, Wong I2
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Objectives: To understand opinions and attitudes on whether and why managed 
entry agreements (MEAs) are needed in today’s healthcare systems, and what can 
make them work. MethOds: Representatives from pharmaceutical companies 
(n= 9) were interviewed, including personnel from pricing, market access, health 
economics and outcomes research and marketing. Payer proxies from the UK, Italy, 
France and Spain, such as health economists and payer advisors (n= 10), were also 
interviewed. Results: Industry stakeholders largely perceived MEAs as a tactical 
means to accelerate market access for premium-priced, specialised medicines - with 
a view to reduce budget impact and/or uncertainty of the clinical benefits; the focus 
depends on the characteristics of the drug and the country. Often, a confidential 
straight discount is preferred. Addressing the uncertainty about clinical benefits was a 
particularly important concern in oncology. The payer proxies typically viewed MEAs 
as instruments to reduce the drug’s budget impact. An important success factor was 
the payers’ motivation to grant access to the novel therapy and view MEAs as appro-
priate to enable it. This means that the MEA should be transparent and simple in its 
framework. Since various stakeholders in the healthcare system are involved, an 
MEA should address their specific incentives. In principle, involving payers during 
the development of an MEA concept could increase its chance of success, but this 
rarely occurs. Several industry respondents identified factors within the company 
as critical e.g. insufficient capabilities, poor coordination in the decision making. 
Country-specific/local constraints play a major role in the feasibility and success of 
MEA implementation. An important limitation is the availability of an appropriate 
the population, with more population groups covered with all three levels of care; 
primary, secondary and tertiary. However, informal sector, the most challenging 
sector worldwide, is not covered through HIO. HIO acts as both service purchaser 
and provider through a widely distributed owned health facilities, in addition to 
outsourcing some secondary and tertiary care services. With the government’s 
plan to implement universal health coverage (UHC) by 2030, HIO is considered 
as the strategic future national purchaser, especially with HIO long experience, 
covering more than half of the population. However, HIO needs to acknowledge 
its structural and operational challenges, and address them, in order to be able 
to carry on this responsibility of being the nation’s health insurer. Objectives: 
This paper discusses the capabilities of the current HIO, highlighting its strengths 
and challenges that need to be addressed before being able to be the sole health 
services purchaser in Egypt. MethOds: A qualitative study, using information 
from the literature and official government documents, describing the laws and 
regulations that govern the work of HIO. It also provides insights into some of the 
foreseen challenges from a health system perspective, discussing challenges to 
be faced by HIO, and other stakeholders like private health insurance and phar-
maceutical companies. It will also provide recommendations on how to overcome 
some of these challenges in the future. Results: Allignment between different 
stakeholders; e.g. government, pharma and healthcare professionals is a must 
to achieve UHC in Egypt. cOnclusiOns: HIO is the strategic national payer in 
Egypt, but this requires structural and operational reform, so that its objective 
of UHC.
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stAte of tHe ARt of medicAl ReGisteRs in switzeRlAnd 2015: moRe 
Questions tHAn AnsweRs
Twerenbold C1, Gratwohl A2, Eichler K1, Hostettler S3, Brügger U1
1Zurich University of Applied Sciences, Winterthur, Switzerland, 2University Hospital Basel, Basel, 
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Objectives: Medical registers are recognized as an important tool in health ser-
vices research (HSR) and health technology assessment (HTA). However, optimal 
use remains to be defined. In 2011, the Swiss Medical Association (FMH) launched a 
project to systematically list all medical registers in Switzerland to improve trans-
parency and networking. This interim analysis shows the current state, potential 
weaknesses and needs for action. MethOds: This prospective study analyzed 
function, classification (epidemiological/clinical) and current status of all Swiss 
medical registers listed on the FMH database. We integrated purpose and proper-
ties by a self-developed typology. Based on our findings, we describe current state 
and suggest new directions. Results: 33 registers were classified as clinical, 36 as 
epidemiological, and 4 as “other”. 66 (90%) were active. The purpose of the registers 
(epidemiological surveillance, quality management, prioritization, HTA) was often 
not specified 28 registers were run by a university (14 clinical, 12 epidemiological, 
2 ”other”),35 (10/23/2) by a public institution, 10 (9/1/0) by a commercial company. 
Clinical registers have the highest probability to be run by a commercial company 
(RR= 2.36;[CI: 1.62-3.44]. 37 registers were national (18/ 18/1), 60 national andin-
ternational (82%;33/24/3) and 13 local (0/12/1). 30 registers (41%) were manda-
tory with no significant differences between the different types. 4 registers were 
linked to HTA decision making. There was an overlap in 4 trauma registers and 
we identified registers that are not listed in the FMH database. Only 6 clinical 
registers have an auditing system in place (9%; 95%-CI 2-14;), none a standard-
ized quality management system. cOnclusiOns: There is documented goodwill 
to conduct medical registers in Switzerland, and to make them available to the 
medical community, to HTA and HSR.There appears a need for a quality manage-
ment system and supervision at a higher level to safeguard quality standards and 
transparency.
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usinG finAnciAl incentives to motivAte stAiR use in A woRkPlAce 
settinG: Results fRom A RAndomized contRolled tRiAl
Guan YY, Chen C, Yoong JS
National University of Singapore, Singapore, Singapore
Objectives: The increasing prevalence of obesity, which is associated with physi-
cal inactivity and sedentary lifestyle, continues to increase and pose a substantial 
economic burden in most developed countries. Many workplace wellness programs 
have evolved to integrate the use of financial incentives to promote behaviour 
change and healthier lifestyles. The purpose of the present study was to deter-
mine whether tournament-style financial incentive (individual-level competitive 
prize of S$150) was effective in motivating adults in the workplace to increase 
daily stair usage over a 6-week period between July and October 2014. This study 
incorporates behavioural economic principles, a workplace stairs competition and 
point-of-decision prompts to offer insights on a behavioural reinforcement strategy 
on physical activity. MethOds: Participants (N= 41) were randomized to one of the 
two experimental groups: (i) control group without financial incentives (n= 20) or 
(ii) intervention group with financial incentives (n= 21). Data was collected using a 
self-monitoring steps cum calories tracker app installed into mobile devices of par-
ticipants in both groups. Results: The intervention group significantly increased 
their stair use compared to the control group by a difference of 7,743 steps (95% CI: 
2,889 – 12,598, p= 0.003). Furthermore, participants in the financial incentive inter-
vention group burned 579 more calories, on average, than the control group (95% 
CI: 229 – 930, p= 0.002). There was no sustained significant effect beyond the 6-week 
period of intervention. cOnclusiOns: Participants in the financial incentive inter-
vention group outperformed the control group through increased stair usage, and 
hence physical activity levels. There is evidence that the use of tournament-style 
financial incentives can promote the uptake of physical activity, however this effect 
attenuates over time and is not sustained beyond the period of intervention. Further 
research should be broadened to include investigating novel mHealth technologies 
that increase stair use and multicomponent interventions that promote physical 
activity for a sustained period of time.
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life expectancies in the world, has invested heavily in domestic R&D and gener-
ics manufacturing in response to the U.S. embargo, and has been successful with 
achieving marketing authorization in multiple countries for its biopharmaceutical 
products. In Iran, international sanctions have led the government to encourage 
domestic production, which supplies 70-90% of the market. A possible relaxing of 
sanctions pending a deal on Iran’s nuclear program may pave the way for a multi-
national presence and increasing access to life-saving medicines. cOnclusiOns: 
In general, the lifting of economic sanctions is observed to have positive impact on 
innovative pharmaceuticals, from both market access and technology transfer per-
spectives. The imposition of sanctions, however, may open the opportunity for local 
manufacturing and industrial innovation. Regardless of commercial and broader 
economic consequences, the lack of access to innovative pharmaceuticals may 
compromise optimal health care delivery in those affected countries.
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Recent uPdAte to RussiA’s essentiAl dRuGs list And seven 
nosoloGies: clinicAl diffeRentiAtion And locAl mAnufActuRinG 
imPlicAtions foR new dRuG inclusion
Duttagupta S1, Yampolsky D1, Chowdhury CA2
1CBPartners, New York, NY, USA, 2New York, NY, USA & London, UK
Objectives: The objective of this study was to assess implications of the recent 
update to Russia’s Essential Drugs List (EDL) and Seven Nosologies (VZN) on the 
access of the local pharmaceutical market in the context of various economic pres-
sures. MethOds: This study was based on the review of current and past iterations 
of the EDL and VZN, various policy changes, as well as economic and health outcome 
indicators. In addition, a pragmatic literature review was undertaken to assess the 
impact of the EDL and VZN updates on the current market access environment in 
Russia. Results: The 2015 EDL, which was previously updated in 2012, includes an 
additional 50 therapies, some of which are reimbursed through the VZN. Five new 
molecules were included within the VZN, including treatments for hemophilia, a 
cure for Gaucher’s disease, and a second-line therapy for multiple myeloma, bring-
ing the total to 23 therapies since its implementation in 2008. The 2013 decision to 
delegate the financial responsibilities (tenders) and implementation of the VZN to 
regional authorities by January 2015 to alleviate federal burden, did not materialize 
as expected, mainly due to cost concerns. 67% of 608 EDL therapies are manufac-
tured domestically, which is a reflection of their evolving pharmaceutical access 
policy due to economic pressure; in addition, only 35% of the 20,000 INNs marketed 
in Russia are reimbursed at the federal or state level while the rest are paid out-
of-pocket. cOnclusiOns: The expansion of the EDL and VZN have made some 
innovative therapies available to certain populations that were previously unable to 
access these high-cost treatments. In addition, due to economic uncertainties, laws 
have been enacted to restrict the admission of foreign drugs to state procurement 
if equivalent INNs are available through local manufacturers.
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HeAltH economics in immunizAtion decision-mAkinG – Results fRom 
A systemAtic liteRAtuRe ReseARcH And A stAkeHoldeR symPosium in 
GeRmAny
Ultsch B1, Damm O2, Perleth M3, Wichmann O1
1Robert Koch Institute, Berlin, Germany, 2School of Public Health, Bielefeld University, Bielefeld, 
Germany, 3Gemeinsamer Bundesausschuss (G-BA), Berlin, Germany
bAckgROund: Immunization decision-making (IDM) is usually based on multiple 
sources of evidence. Health economics (HE) has become increasingly relevant in IDM 
as one aspect to be considered. Objective of this study was to generate a consensus 
among stakeholders on how to implement HE into IDM in Germany. MethOd: We 
conducted a systematic literature review in order to identify relevant methods and 
advantages of considering HE evidence in IDM. Furthermore, an overview of IDM 
in several European countries was compiled based on literature. The generated 
evidence was used to prepare a national stakeholder symposium in January 2015 
on which representatives from academia, politics, industry, administration and 
patient-support groups were able to discuss different options on how to implement 
HE into IDM. Results: Based on the literature review five core advantages from 
considering HE aspects in IDM were identified: (I) modelling of future vaccine related 
public health effects; (II) identification of the most efficient vaccination strategy; 
(III) identification of critical input parameter; (IV) budget-impact-analysis; and (V) 
decision-making based on an incremental cost-effectiveness threshold. A recently 
conducted survey showed that most European countries consider HE in IDM. This 
is done (a) most frequently via an informal appraisal, (b) rarely by using a cost-
effectiveness threshold (4 countries), and (c) never by applying multiple-criteria 
decision-analyses. After key-note lectures, group-works and panel discussions, the 
majority of stakeholders had the opinion that in Germany the core advantages of (I) 
to (III) should be taken into account and decisions should be derived from an infor-
mal appraisal. discussiOn: Most of the invited stakeholders acknowledged the use 
of HE in IDM. There was consensus that in Germany a cost-effectiveness threshold 
is no option. However, HE might be considered in IDM to compare different vac-
cination strategies and highlight the potential (economic) benefits of vaccination.
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How to institutionAlize tHe “knowledGe to Action” fRAmewoRk foR 
HeAltH tecHnoloGy Assessment?
Espinoza MA1, Cabieses B2
1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Universidad del Desarrollo, Santiago, 
Chile
Objectives: The institutionalization of health technology assessment (HTA) 
remains a major challenge for many countries. Normative, political and social vari-
ations across nations limit the transference of HTA institutionalization models 
that have been implemented elsewhere. The “Knowledge to action” (KA) model 
has proven to reduce the “evidence-practice” gap through a systematic method 
of linking evidence to implementation and monitoring processes. The objective of 
data infrastructure, and some companies are advanced than others in tackling this 
issue. cOnclusiOns: All respondents believed that MEAs will be used more fre-
quently. Performance-based schemes, while more difficult to be put in practice, are 
expected to become critical in disease areas like oncology.
HeAltH cARe use & Policy studies – conceptual Papers
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tHe new tecHnoloGy cost-effectiveness cHecklist: intRoducinG A 
PRActicAl Guideline foR tHe selection of HeAltH tecHnoloGies
Calderon MR, Salvatierra Ocano A, Roording R
Novartis Farmacéutica, S.A (AC), Guatemala, Guatemala
bAckgROund: The increasing focus on healthcare costs, aging of populations and 
rising costs of drug development require an effective approach to ensure the rational 
uptake and diffusion of technologies by health systems. Health stakeholders want 
safe, appropriate and effective healthcare with enduring results at a reasonable cost, 
particularly in environments where resources are scarce. In spite of much research, 
methodologies and recommendations, a simple solution to make budget allocations 
or procurement decisions is still needed by many decision makers. AppROAch: A 
user-friendly and read-do checklist could facilitate the assessment of cost-effec-
tiveness of technologies, particularly new, innovative high cost drugs. The aero-
nautical industry (pre-flight safety checklist), World Health Organization/Harvard 
School of Public Health (pre-surgical safety checklist) and public health services 
(pre-disaster or disease preparedness checklists) have successfully prevented 
and reduced air traffic accidents and morbidity and mortality secondary to sur-
gical interventions, diseases and natural disasters through the implementation 
of safety checklists. pRActicAl iMplicAtiOns: In pharmacoeconomics, as in 
aviation, medicine and public health, a checklist can help ensure consistency and 
completeness in carrying out the complex technology selection task improving 
the decision maker´s communication and consistency of information and data, 
facilitating the decision-making process and determining the most cost-effective 
options. This checklist could also be a useful tool to negotiate value added services, 
managed-entry agreements and risk-sharing arrangements to reduce the cost of 
drugs. cOnclusiOns: A generic “New Technology Cost-Effectiveness Checklist”, 
intended to be modified as needed to fit local requirements, could guide evidence-
based decisions in resource-limited settings. In turn, it may become the tool to 
reach the universal goals of patients, providers, payers and policy-makers to (1) get 
the best drug and technology quality at the lowest cost and with reasonable access, 
and (2) enhance healthcare partnerships and solutions towards improved individual 
and population health outcomes.
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Objectives: Recently the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) 
have been introduced. The scale is supposed to assist decisions about value and 
cost-effectiveness of new cancer therapies. This is done by classifying therapeutic 
advances according to their relative clinical benefit according to pre-defined cri-
teria. The objective of the present study was to investigate the scale from a health 
economics perspective. MethOds: We conducted a critical appraisal of the build-
ing blocks of the scale in order to assess potential limitations to using the instru-
ment to inform policy. Results: Several issues that makes the scale problematic 
were identified. Three key areas of concern were: ESMO-MCBS uses different scales 
depending on if the intent of the therapy of to be curative or not. It is impossible to 
compare two cancer treatments which both have effect on survival and quality of 
life if the intension of the two therapies are different, yet they would compete for the 
same resources within the health care system. The ranking used is created based on 
expert opinion. It is unclear how these rankings would relate to the preferences of 
the patients or the general public. The scale relies on clinical trials as the evidence 
base. What matters for reimbursement agencies, payers and health care providers 
is how well the new treatment opportunity performs in clinical practice, in relation 
to existing therapeutic alternatives. cOnclusiOns: There are limitations to the 
ESMO-MCBS at present as a measure of value. One important aspect that would 
merit further study is to validate how well the scale is able to discriminate between 
more and less valuable therapies as perceived by reimbursement bodies, by for 
instance comparing the rankings of therapies according to ESMO-MCBS to rankings 
based on estimated gains in survival and quality-adjusted survival.
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Objectives: The objective of this study was to analyze the impact of imposed 
and/or withdrawn economic sanctions on various countries on access to innova-
tive pharmaceuticals, market access, and health outcomes. Recent geopolitical and 
pharmaceutical market dynamics related to Russia, Cuba, and Iran. MethOds: This 
study examined the current health care financing options and market access impli-
cations of pharmaceuticals in Russia, Cuba, and Iran in light of the introduction or 
removal of sanctions on these markets. Intellectual property regulations, healthcare 
financing and procurement options, and domestic R&D investment were the key 
metrics evaluated in this research. Results: Due to sanctions imposed, Russia has 
pivoted from nearly solely an importation pharmaceutical market, to developing 
relevant policy framework to provide preferential access to locally-manufactured 
products (both from foreign and local manufacturers). Cuba, with one of the highest 
